CompletedNot applicableNCT04083859

Digital Outreach Intervention for Lung Cancer Screening

mPATH-Lung (mobile Patient Technology for Health - Lung) is an innovative digital outreach program that identifies patients who qualify for lung cancer screening and helps them get screened. The study will: 1) Determine the effect of mPATH-Lung on receipt of lung cancer screening in a pragmatic randomized-controlled trial conducted with primary care patients in two large health networks, 2) Elucidate the drivers of patients' screening decisions and screening behavior; and 3) Explore implementation outcomes that will impact the sustainability and dissemination of mPATH-Lung using program data, surveys, and interviews. This project will determine how mPATH-Lung affects patients' screening decisions and their completion of screening.

Checked against the public recordLast updated Jun 25, 2025 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations2
SponsorWake Forest University Health Sciences
01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Other: mPATH-Lung; Other: Lung health video
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Meet the Medicare criteria for lung cancer screening, as updated in February 2022: * Age 50 - 77 years * Smoked at least 20 pack years * Current smoker or quit smoking within the past 15 years * Be scheduled to see a primary care provider within the health network in the next 3-4 weeks * Have a patient portal account or cellphone number listed in the electronic health record Exclusion Criteria: * Patients flagged as needing a language interpreter in the electronic health record (electronic messages and intervention is delivered in English only). * Those for whom lung cancer screening would be inappropriate: * Prior history of lung cancer * Chest CT within the last 12 months * Those with medical conditions predicting shorter life expectancy * Patients whose home address is not within the state of North Carolina. (Due to telehealth guidelines)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of North Carolina- Chapel HillChapel Hill, North Carolina
  • Wake Forest Baptist Medical CenterWinston-Salem, North Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 25, 2025. Always confirm current availability with the study team.

View original record ↗